Eligible studies included preclinical or clinical investigations of CD47/TSP1 in AAA or related vascular diseases, mechanistic analyses of macrophage-driven inflammation and matrix degradation, and reports on CD47-targeted therapeutics relevant to vascular pathology. The gene discussed is CD47; the disease is triple-A syndrome.